COVID-19 Rapid Testing

Rapid & Reliable Coronavirus Testing with the Fortress Total Antibody Device

Affordable

Results in minutes

No specialist equipment needed

Small sample size required

The Fortress COVID-19 Total Ab Device is a single use, rapid device for qualitative detection of total antibodies against 2019 novel coronavirus (SARS-CoV-2) in human serum, plasma or whole blood specimens. The kit is intended for screening of patients suspected for infection with SARS-CoV-2, and as an aid in the diagnosis of the coronavirus disease 2019 (COVID-19).

Una Health and Fortress Diagnostics are partnering with the Department of Health & Social Care in the Real Time Assessment of Community Transmission (REACT) Study into COVID-19. The REACT study is being led by Imperial College London and Ipsos MORI and is looking to understand how many people are currently infected, or have been infected, with the COVID-19 virus. Through the partnership, the Fortress COVID-19 Total Antibody Device, a single use, rapid device for qualitative detection of total antibodies against novel coronavirus (SARS-CoV-2) has been supplied for the study.

 

The Fortress COVID-19 Total Antibody IgG/IgM Test…

> High sensitivity & specificity

> Affordable

> High quality & easy-to-use

> Little or no additional equipment required

> Quick results – Within 10 minutes

> Possibility to store at room temperature for extended length of time

 

The ability to mass test has been crucial in the fight against COVID-19. Una Health are at the forefront of this fight and are devoted to doing our bit during the outbreak. Our verified testing options are available now to enable you to provide rapid and reliable diagnosis of coronavirus.

Contact us to find out more

Contact our team









What we do with your data

NG Biotech CARBA 5
Because there's more to public health than COVID-19...

"We love the ease and accuracy of the NG CARBA-5 lateral flow test. It has decreased our turnaround times and means we no longer need the reference laboratory to confirm our presumptive CPO results." - Holly Ciesielczuk, Senior Clinical Scientist at Barts Health NHS Trust

Read More